Introduction
years after the restoration of a normal renal function.
The alternative view claims that there is at present Do amyloid deposits regress after successful therapy no conclusive evidence that b 2 M amyloid regresses of their aetiological factors? The issue is of great after transplantation. It is based mainly upon morphoclinical relevance as more and more ecient treatments logical evidence. b 2 M amyloid deposits form bone cysts are developed. It remains hotly disputed, as illustrated readily identified by X-rays. Provided that strict criteria by the fate of dialysis-related (or b 2 M ) amyloidosis. are adhered to, these bone cysts are characteristic of After a successful renal transplantation has fully coramyloid deposition [8] . Thus several studies have rected the b 2 M excretory defect, some studies suggest examined their evolution after renal transplantation that b 2 M amyloidosis regresses [1, 2] , whereas others [3, [5] [6] [7] and demonstrated that they neither disappear hold the opposite view [3] [4] [5] [6] [7] . A recent report of Tan nor even regress in size even after 10 years. Tan et al. et al. [2] , claiming regression after renal transplanta- [2] report similar results but claim that cyst size tion, rekindles this debate.
regresses 'not substantially' without providing quantitative criteria for regression. The persistence of b 2 M amyloidosis is further corroborated by histological evidence of b 2 M amyloid deposits up to 10 years after
Two contradictory views
transplantation [4-6,9].
Two contradictory views are expressed at the present time. The first holds that b 2 M amyloidosis regresses
The validity of SAP scintigraphy to quantify b 2 M after transplantation. It relies mainly on changes in amyloid deposits focal uptake of labelled serum P component (SAP), a protein co-deposited with amyloid fibrils. Scintigraphy is used to detect as well as to assess, semiquantitatively, The validity of each view hinges upon the quantitative significance of the chosen marker, either scintigraphy amyloid deposits. Tan et al. [2 ] report that after a median post-transplant delay of 4.5 years, labelled or morphological evidence.
Let us first consider the value of SAP scintigraphy SAP uptake decreases at at least one initially positive site in eight of nine transplanted patients, falling below to detect and quantify amyloid deposits. Hawkins et al.
[10] pointed out a few years ago the diculties of an detection limits in six sites from three patients. They '… accurate estimation of tissue amyloid content amyloidosis, the specificity of the SAP scan might be because histological examinations cannot reasonably wanting [4 ] . It is as yet unknown whether the probable sample more than a very small proportion of the aspecific splenic uptake also regresses after renal transinvolved organs and, even then, light microscopy exam-plantation; such information might cast new light on ination of green birefringent areas may not reflect the significance of changes in labelled SAP uptake. quantitatively the absolute amount of amyloid fibril Only inadequate specificity is relevant to the present deposits'. In mice with casein-induced, massive amyl-discussion. Still, it should be remembered that the oidosis of the spleen and liver, there is little variation sensitivity of SAP scintigraphy is also limited. The in the proportion of the injected dose of labelled SAP technique fails to identify b 2 M amyloid deposits in that localizes; correlation is thus excellent, but the 63% of clinically symptomatic shoulders whereas SAP range of amyloid deposit size is rather narrow. By does not accumulate in the hips, a frequent site of b 2 M contrast, in the amyloid-enhancing factor induced amyloid deposition [1] . In other types of amyloidosis, model, amyloid deposition varies markedly between sensitivity falls to 50% in the kidneys and to 25% in mice; correlation between histological score and local-the heart [12 ]. ized labelled SAP proves 'imperfect' [10] .
A last cause of concern stems from the variability In man, correlation between SAP accumulation and of the observations made in transplanted patients. In quantitation of amyloid is even less clear. In their a first study of five patients with clinical and historecent paper, Tan et al. [2] quote six references from logical (n=4) evidence of amyloidosis while on dialysis, their own group addressing this critical issue. Nelson et al. [1] did not observe labelled SAP uptake Interestingly, only two provide original data. The first 0.8 to 2.4 years after a successful graft, a finding [11 ] concerns a single patient with AL amyloidosis. At interpreted as evidence of b 2 M amyloid regression. By autopsy, the percentage of injected tracer expressed contrast, 5 years later, the same group [2] describes a per 100 g of tissue is weakly correlated with a significant uptake of labelled SAP in eight of 9 patients, semiquantitative histological assessment of amyloid despite a longer delay after transplantation (median deposits. For tissues with similar amyloid involvement, 4.5 years). This discrepancy raises the issue of the uptake varies fivefold. The second reference is an technical problems inherent to quantitative assessments extended abstract published in the proceedings of a of external scintigraphy. 1993 international symposium on amyloidosis [12 ] .
The diculty of a histological quantitation of sysAutopsy material was harvested in 15 patients with temic amyloid deposits, the questionable correlation various types of amyloidosis, 8 h to 5 months after a between SAP labelling and quantity of deposited labelled SAP study. Amyloid deposits were quantitat-amyloid both in mice and man, the limited specificity ively graded by two experienced assessors in tissue and sensitivity of the technique, taken together with sections stained with Congo red. Results were com-the apparent variability of external scan results in pared with labelled SAP uptake, the amount of native transplanted patients call thus for a very cautious unlabelled SAP extracted from available organs, and interpretation of post-transplantation changes of the when possible the residual quantity of labelled SAP SAP scan. within them. In spleen and liver, correlation between histological assessment and scintigraphic estimates is said to be excellent (r=0.90 and 0.95 respectively). For other organs, however, correlation is not assessed but The valididity of morphological method should be rather poor as a result of poor sensitivity ( 50% for the kidneys and 25% for the heart). Native
The alternative view that b 2 M amyloidosis does not SAP extracted from liver, spleen, kidneys and heart regress significantly after renal transplantation relies 'correlates with histological score' (no r value given). mainly upon morphological evidence. In the four patients given radioactive SAP 1-118
The significance of bone amyloid cysts hinges upon days beforehand, residual radioactivity in various the quantitative relationship between their size and (undefined ) tissues is proportional to the amount of their actual amyloid content. The demonstration of native SAP extracted from them. In the absence of persistent b 2 M amyloid deposits in some cysts [6 ] or detailed methodological, clinical, and individual in synovia [4,5] does not rule out the possibility that information, these results are not convincing. the deposits were initially larger and that fibrous tissue None of these studies included patients with b 2 M progressively replaces amyloid in bone cysts, thus amyloidosis. In this group of patients, the limited preventing cyst regression. Furthermore the relevance specificity of labelled SAP scans is a further cause of of amyloid bone deposits to the total amount of concern when its ability to monitor amyloid deposits precipitated b 2 M amyloid remains to be demonstrated. is discussed. Labelled SAP accumulation in the spleen For instance Tan et al. [2] have suggested that bone has been reported by Nelson et al. [1 ] in eight of 22 amyloid might mobilize more slowly from bone cysts patients (36%) dialysed for more than 10 years.
than from other sites, a hypothesis still to be tested. However, detailed autopsy studies [13] in 18 patients These various limitations have to be kept in mind dialysed for 10-23 (mean 13.5) years have revealed whenever the post-transplantation regression of b 2 M histological evidence of spleen amyloidosis in only one case (5%). Such a discrepancy suggests that in b 2 M amyloidosis is discussed.
Conclusion
We have yet to conceive a meaningful protocol capable Whatever the final answer, the defendants for both Introduction multiple accesses and therefore seems to rely on a post hoc definition of the group at highest risk. It is plausible A letter to the editor of Nephrology Dialysis that a first access failure predicts future failures and Transplantation in this issue ( p. 850) suggests that poor outcomes, and therefore that the primary focus haemodialysis patients with a history of vascular access of research on vascular access should be directed at failure are at higher risk of death. The analysis com-factors leading to a first access failure in order to pares patient survival between patients who had only prevent this first event. Potential risk factors for poor outcomes may include (1) failure to place a permanent 
